BioAtla Q3 2023 Cash, Cash Equivalents $141.3M
Portfolio Pulse from Benzinga Newsdesk
BioAtla reported its Q3 2023 cash and cash equivalents to be $141.3 million.
November 07, 2023 | 9:04 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BioAtla's Q3 2023 financial report shows a cash and cash equivalents balance of $141.3 million.
The news is directly related to BioAtla's financial health. However, without additional context such as previous quarters' figures or analysts' expectations, it's hard to predict the impact on the stock price. Therefore, the score is neutral.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100